I think it will be a standard poster showing initial safety and signs of activity. The interesting part will be the biology (no conditioning +/- combo with mAbs), but this is more proof-of-mechanism.
This new update is going to be more informative, but it still will be a small cohort, especially spread across multiple regimens, including Regimen C (cetuximab combo) and Regimen E (trastuzumab combo). So far, safety remains the strongest story. A key question will be if the first CRC signal is reproducible.
Market Data 
Markets 
AI
